secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHEMBIO DIAGNOSTICS, INC. (—)
CIK:        0001092662
Form:       8-K
Filed at:   2023-04-27T23:59:59+00:00
Accession:  0001140361-23-021050
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biosynex completes ~$17.2M acquisition of Chembio Diagnostics; Chembio delisted from Nasdaq
--------------------------------------------------------------------------------

- Biosynex acquired Chembio for $0.45 per share in cash, transaction value ~$17.2 million.
- Tender offer received ~50.9% of outstanding shares; merger completed April 27, 2023 under Nevada law.
- Chembio becomes wholly-owned indirect subsidiary of Biosynex; stock ceased trading on Nasdaq.
- Credit agreement with Perceptive Credit Holdings terminated; all obligations repaid at closing.
- Larry Abensur and Thierry Paper appointed as officers; all prior directors/officers removed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1092662/000114036123021050/0001140361-23-021050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1092662/000114036123021050/brhc20052113_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-021050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer